



## Announcement Summary

**Entity name**

CLARITY PHARMACEUTICALS LTD

**Date of this announcement**

Tuesday December 02, 2025

**The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**Total number of +securities to be issued/transferred**

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
CU6AAM	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	12,797	10/11/2025
CU6AAM	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	89,892	17/11/2025
CU6AAM	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	2,262,087	25/11/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

CLARITY PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted securities.

**1.2 Registered number type**

ACN

**Registration number**

143005341

**1.3 ASX issuer code**

CU6

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

2/12/2025

For personal use only



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

has an existing ASX security code ("existing class")

For personal use only



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**ASX +security code and description**

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

**Date the +securities the subject of this notification were issued**

10/11/2025

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

No

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 10 November 2026

25% on 10 November 2027

50% on 10 November 2028

Issue details

**Number of +securities**

12,797

**ASX +security code and description**

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

**Date the +securities the subject of this notification were issued**

17/11/2025

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

No

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:  
 25% on 17 November 2026  
 25% on 17 November 2027  
 50% on 17 November 2028

## Issue details

**Number of +securities**

89,892

**ASX +security code and description**

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

**Date the +securities the subject of this notification were issued**

25/11/2025

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Alan Taylor	Alan Taylor	517,916
Michelle Parker	Michelle Parker	209,904
Colin Biggin	Colin Biggin	199,909

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Vesting of the options is subject to continuous employment by the Company during the Performance Period (1 July 2025 - 30 June 2028 inclusive) and the achievement of specific performance hurdles as outlined in the 2025 Notice of Annual General Meeting. The issue of the options was approved by shareholders at the 2025 Annual General Meeting.



## Issue details

**Number of +securities**

927,729

**ASX +security code and description**

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

**Date the +securities the subject of this notification were issued**

25/11/2025

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Alan Taylor	Alan Taylor	744,922
Michelle Parker	Michelle Parker	301,906
Colin Biggin	Colin Biggin	287,530

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Vesting of the options is subject to the achievement of Total Shareholder Return (TSR) Performance Criteria and continuous employment during the Performance Period (1 July 2025 - 30 June 2028 inclusive) as outlined in the 2025 Notice of Annual General Meeting. The issue of the options was approved by shareholders at the 2025 Annual General Meeting.

## Issue details

**Number of +securities**

1,334,358



## Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CU6 : ORDINARY FULLY PAID	372,030,071

**4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	20,548,867
CU6AN : OPTION EXPIRING 10-MAY-2026 EX \$0.94	1,175,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13

For personal use only